Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | SGK1 | O00141 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 7/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 7/20 | 0.41 |
| ▸ | SCN1A | P35498 | 5/20 | 0.41 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20095939 | 0.89 | SCN9A (0.56) | SCN9AHSD11B1HTTSCN5ASCN8A | |
| SCHEMBL20096114 | 0.79 | SCN9A (0.56) | SCN9AHSD11B1HTTSCN5ASCN8A | |
| SCHEMBL20063614 | 0.76 | SCN9A (1.00) | SCN9A | |
| SCHEMBL20182483 | 0.73 | SCN5A (0.62) | SCN9ASCN5ASCN8ASCN1A | |
| SCHEMBL320738 | 0.68 | SLC22A12 (0.56) | SCN9ASGK1SCN5ASCN8ASCN1A | |
| SCHEMBL16757015 | 0.68 | SCN1A (0.62) | SCN9ASCN5ASCN8ASCN1A | |
| SCHEMBL19614071 | 0.68 | SCN1A (0.65) | SCN9ASCN5ASCN8ASCN1ANR1I2 | |
| SCHEMBL20096109 | 0.68 | SCN5A (0.62) | SCN5ASCN8ASCN1A | |
| SCHEMBL5911677 | 0.68 | ALDH1A1 (0.60) | HSD11B1HTT | |
| SCHEMBL19008524 | 0.68 | SCN9A (0.57) | SCN9ASCN5ASCN8ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| WO-2018072602-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SCN9A 1478/4885HSD11B1 316/4885SGK1 1712/4885 |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | SCN9A 1478/4885HSD11B1 316/4885SGK1 1712/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SCN9A 1501/4885HSD11B1 323/4885SGK1 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.